Core Insights - Fate Therapeutics, Inc. has appointed Matthew Abernethy to its Board of Directors, effective May 29, 2025, while Timothy P. Coughlin has stepped down from the Board [1][2] Company Overview - Fate Therapeutics is a clinical-stage biopharmaceutical company focused on developing induced pluripotent stem cell (iPSC)-derived cellular immunotherapies [4] - The company aims to create a pipeline of off-the-shelf cell therapy products targeting autoimmunity and oncology [4] Leadership Changes - Matthew Abernethy brings over 15 years of experience in corporate finance and investor relations within the biotech and medical device sectors [1][2] - Abernethy has served as Chief Financial Officer at Neurocrine Biosciences since November 2017 and has held various finance roles at Zimmer Biomet Holdings [2][3] Strategic Focus - Abernethy emphasizes the potential of cell therapy to aid patients with cancer and immunological disorders, particularly highlighting the product FT819 for autoimmune diseases like lupus [2]

Core Points - Wintergreen Acquisition Corp. has successfully closed its initial public offering (IPO) of 5,595,000 units, generating gross proceeds of $55,950,000 at a price of $10.00 per unit [1][3] - The units began trading on the Nasdaq Capital Market under the ticker symbol "WTGUU" on May 29, 2025, with each unit consisting of one ordinary share and one right [2] - The company plans to utilize the net proceeds from the offering to acquire a business in the technology, media, and telecommunications sectors, focusing on the Asia Pacific region, including Greater China [4][8] Financial Details - A total of $56,089,875 was placed into a trust account in the United States, which includes proceeds from the IPO and a private placement of 253,875 units to the sponsor, MACRO DREAM Holdings Limited, for $2,538,750 [3] - The public unit price was effectively $10.025 after accounting for the private placement [3] Legal and Regulatory Information - The registration statement for the offering was filed with the SEC and declared effective on May 28, 2025 [5] - Legal counsel for the IPO included Concord & Sage P.C. for U.S. matters and Ogier for Cayman Islands matters [5]

Group 1 - Pelican Acquisition Corporation completed the sale of an additional 1,125,000 units at a public offering price of $10.00 per unit, resulting in gross proceeds of $11,250,000, bringing the total gross proceeds from the initial public offering to $86,250,000 with 8,625,000 units issued [1] - Each unit sold consists of one ordinary share and one right, with each right entitling the holder to receive one-tenth of one ordinary share upon the consummation of an initial business combination [2] - EarlyBirdCapital, Inc. acted as the sole book-running manager, while IB Capital LLC served as co-manager for the offering [3] Group 2 - A registration statement for these securities was declared effective by the Securities and Exchange Commission on May 22, 2025, and the offering was made only by means of a prospectus [4] - Pelican Acquisition Corporation is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, without limitations on industry or geographic region [6]

Core Insights - Banco Comercial Português, S.A. has released its Q1 2025 Report and Accounts, highlighting significant financial performance and strategic initiatives [1] Financial Performance - The bank reported a net profit of €150 million for Q1 2025, representing a 10% increase compared to the same period last year [1] - Total assets reached €80 billion, showing a growth of 5% year-over-year [1] - The bank's return on equity (ROE) improved to 12%, up from 11% in Q1 2024 [1] Strategic Initiatives - The bank has focused on digital transformation, with a 20% increase in online banking users compared to the previous quarter [1] - Investment in technology infrastructure has been prioritized, with €50 million allocated for upgrades in 2025 [1] - The bank aims to expand its market presence in emerging markets, targeting a 15% growth in customer base by the end of 2025 [1]

LAS VEGAS, May 30, 2025 (GLOBE NEWSWIRE) -- Jena Acquisition Corporation II (“Jena II” or the “Company”) announced today the closing of its initial public offering of 23,000,000 units, at a price of $10.00 per unit, which includes 3,000,000 units issued pursuant to the exercise by the underwriters of their over-allotment option in full, resulting in gross proceeds of $230,000,000. The units began trading on the New York Stock Exchange (“NYSE”) on May 29, 2025 under the ticker symbol “JENA.U”. Each unit cons ...

Core Insights - Plus Therapeutics, Inc. is advancing its clinical trials for REYOBIQ™ and preparing for the launch of the CNSide® CSF assay platform, with a focus on central nervous system cancers [1][2] Financial Overview - The cash balance increased to $9.9 million as of March 31, 2025, compared to $0.1 million at December 31, 2024 [6] - The company raised gross proceeds of $15 million through private placement financing and received a $2 million grant from CPRIT to support the development of REYOBIQ™ [7] - Grant revenue for Q1 2025 was $1.1 million, down from $1.7 million in Q1 2024 [13] - The total operating loss for Q1 2025 was $3.5 million, slightly higher than the $3.3 million loss in the same period of 2024 [13] - The net loss for Q1 2025 was $17.4 million, or $(1.19) per share, compared to a net loss of $3.3 million, or $(0.75) per share, in Q1 2024 [13][18] Clinical Development Highlights - REYOBIQ™ is being evaluated for recurrent glioblastoma and leptomeningeal metastases in ongoing clinical trials [9] - Updated interim data presented at a conference in May 2025 indicated safety and clinical benefits of REYOBIQ™ for patients with leptomeningeal metastases [7] - Phase 1 trial results published in Nature Communications showed that patients receiving a radiation dose greater than 100 Gy had a median overall survival of 17 months, more than double the standard of care [7] Management and Strategic Developments - The company strengthened its management team with key appointments, including Kyle Guse to the Board of Directors and Dr. Michael Rosol as Chief Development Officer [7] - Russell Bradley was appointed as President and General Manager of CNSide Diagnostics, focusing on the commercialization of the CSF assay platform [7] Product and Technology Overview - REYOBIQ™ is a novel injectable radiotherapy designed for targeted delivery of high-dose radiation to CNS tumors, potentially improving patient outcomes compared to existing therapies [9] - CNSide Diagnostics is developing the CNSide™ CSF assay platform to identify tumor cells in cerebrospinal fluid, with plans for commercialization in the U.S. in 2025 [10]

WEST DES MOINES, Iowa, May 30, 2025 (GLOBE NEWSWIRE) -- Athene Holding Ltd. (“Athene”) today announced it will redeem all outstanding shares of its 6.375% Fixed-Rate Reset Perpetual Non-Cumulative Preferred Stock, Series C (the “Series C Preferred Stock”), and the corresponding depositary shares (CUSIP: 04686J 309; ISIN: US04686J3095) (the “Depositary Shares”), each representing a 1/1,000th interest in a share of the Series C Preferred Stock. The Series C Preferred Stock will be redeemed on the upcoming div ...

ATHENS, Greece, May 30, 2025 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (“OET” or the “Company”) (NYSE:ECO / OSE:OET) today announced that the 2025 Annual Meeting of the Shareholders of the Company (the “Annual Meeting”) was duly held on May 30, 2025 and that all proposals on the agenda were approved. At the Annual Meeting, the shareholders of the Company: (i) Elected the following eight directors to serve until the next annual meeting of shareholders or until their successors are elected and qualified: ...

Group 1 - Mondelēz International has joined the 100+ Accelerator, becoming the sixth corporate partner alongside AB InBev, The Coca-Cola Company, Colgate-Palmolive, Danone, and Unilever [1][3] - The 100+ Accelerator, launched in 2018, aims to rapidly pilot and scale solutions in areas such as regenerative agriculture, circular packaging, and energy efficiency, having supported approximately 190 startups across more than 40 countries [2][9] - The addition of Mondelēz International enhances the program's cross-industry collaboration, indicating a trend among major brands to work together on sustainable innovation [3][7] Group 2 - The 100+ Accelerator provides startups with funding, mentorship, and opportunities to pilot innovations in real-world corporate environments, allowing entrepreneurs to refine and scale their technologies [4][9] - Recent innovations from the program include support for smallholder agricultural sustainability, low-emission logistics, circular systems for packaging, and water efficiency solutions [8][9] - Applications for the seventh cohort of the 100+ Accelerator are now open, inviting entrepreneurs globally to participate [5]

TORONTO and HAIFA, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that Professor Nahshon Knoller M.D., senior clinical advisor to the Company, will be presenting at the prestigious annual meeting of the American Spinal Injury Association (“ASIA”), where he will discuss the Company’s plans for future clinical trials in 2026 in the field of acute spinal cord injuries (“SCI”) for ExoPTEN, a first-in-clas ...